{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:40:03Z","timestamp":1773326403210,"version":"3.50.1"},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The recent approval of monoclonal antibodies for the treatment of Alzheimer's disease represents a significant advancement in neurology. This accomplishment coincides with a worrisome trend: the increasing hegemony of large corporate healthcare organizations and commercial laboratory corporations in the supply of these new medications. This editorial examines how corporate influence undermines the traditional physician\u2013patient relationship, diminishes neurologist autonomy, and signals a broader incursion into neurological practice by nonspecialists. The current situation in Brazil, compared with the United States and Europe, including the United Kingdom, is discussed, and strategies are proposed to maintain the integrity of neurological therapy amid growing corporate influence in the medical field.<\/jats:p>","DOI":"10.1055\/s-0046-1817020","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:50:36Z","timestamp":1773276636000},"page":"001-005","source":"Crossref","is-referenced-by-count":0,"title":["The corporate takeover of Alzheimer's treatment: a crisis in neurological autonomy?"],"prefix":"10.1055","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-7223","authenticated-orcid":false,"given":"Abelardo Q.C.","family":"Araujo","sequence":"additional","affiliation":[{"name":"Instituto de Neurologia Deolindo Couto, Rio de Janeiro RJ, Brazil."},{"name":"Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"C H Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"06","key":"ref2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"J R Sims","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease","volume":"38","author":"J Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"07","key":"ref4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40263-024-01097-w","article-title":"A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease","volume":"38","author":"M H Rosenbloom","year":"2024","journal-title":"CNS Drugs"},{"key":"ref5","first-page":"819","article-title":"Effects of Pimavanserin on Neuropsychiatric Symptoms in Alzheimer's Disease","volume":"391","author":"Pimavanserin Trial Investigators","year":"2024","journal-title":"N Engl J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/alz.12778","article-title":"Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment","volume":"19","author":"S Mattke","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"01","key":"ref9","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.1038\/s41598-023-36604-4","article-title":"Disparity in the use of Alzheimer's disease treatment in Southern Brazil","volume":"13","author":"M Marco","year":"2023","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"101064","DOI":"10.1016\/j.vhri.2024.101064","article-title":"The Burden of Alzheimer's Disease and Its Costs to a Healthcare System in a Large Population in Brazil","volume":"45","author":"A C Vilarinho","year":"2025","journal-title":"Value Health Reg Issues"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00508-024-02465-8","article-title":"Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic","volume":"137","author":"S Lee","year":"2025","journal-title":"Wien Klin Wochenschr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2024C002","DOI":"10.1590\/1980-5764-DN-2024-C002","article-title":"Use of anti-amyloid therapies for Alzheimer's disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology","volume":"18","author":"B JAP Barbosa","year":"2024","journal-title":"Dement Neuropsychol"},{"issue":"11","key":"ref17","doi-asserted-by":"publisher","first-page":"e16347","DOI":"10.1111\/ene.16347","article-title":"World Federation of Neurology","volume":"31","author":"W Grisold","year":"2024","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"S Crescioli","year":"2025","journal-title":"MAbs"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1817020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:50:42Z","timestamp":1773276642000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1817020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":12,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["s00461817020"],"URL":"https:\/\/doi.org\/10.1055\/s-0046-1817020","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}